November 25, 2016 - By Pete Kolinski · 0 Comments
The stock of Axsome Therapeutics Incorporated (NASDAQ:AXSM) registered an increase of 8.21% in short interest. AXSM’s total short interest was 258,400 shares in November as published by FINRA. Its up 8.21% from 238,800 shares, reported previously. With 35,500 shares average volume, it will take short sellers 7 days to cover their AXSM’s short positions. The short interest to Axsome Therapeutics Incorporated’s float is 2.32%. The stock decreased 4.08% or $0.3 on November 23, hitting $7.05. Axsome Therapeutics Inc (NASDAQ:AXSM) has declined 29.22% since April 22, 2016 and is downtrending. It has underperformed by 34.63% the S&P500.
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $129.52 million. The Firm is engaged in developing therapies for the management of central nervous system disorders, including pain. It currently has negative earnings. It operates in the business of developing novel therapies for the management of CNS disorders segment.
Out of 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Axsome Therapeutics has been the topic of 3 analyst reports since December 14, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, December 15 by Cantor Fitzgerald. The firm earned “Buy” rating on Monday, December 14 by Ladenburg Thalmann. Brean Capital initiated Axsome Therapeutics Inc (NASDAQ:AXSM) on Monday, October 3 with “Buy” rating.
Axsome Therapeutics, Inc., incorporated on January 12, 2012, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. The Company’s product candidate portfolio includes two late-stage candidates, AXS 02 and AXS 05, which the Company is developing for multiple indications. The Firm is also developing AXS 06 for the treatment of chronic pain disorders. AXS 06 is in preclinical development.
Another recent and important Axsome Therapeutics Inc (NASDAQ:AXSM) news was published by Quotes.Wsj.com which published an article titled: “News Axsome Therapeutics Inc.AXSM” on October 30, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski